Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sotera Health ( (SHC) ) has issued an announcement.
On May 11, 2026, Sotera Health entered into an underwriting agreement with certain selling stockholders and Goldman Sachs & Co. LLC for the secondary sale of 31,838,253 shares of its common stock at $15.168 per share. On May 13, 2026, these selling stockholders, affiliated with former private equity sponsors Warburg Pincus and GTCR, completed the sale to the underwriter, with Sotera issuing no new shares and receiving no proceeds, and none of its executive officers participating in the transaction.
Following the completion of the May 13, 2026 offering, Warburg Pincus and GTCR ceased to own any Sotera Health common stock, triggering the termination of the existing stockholders’ agreement and ending their special corporate governance rights. Directors previously designated by these sponsors may remain on the board and its committees until their current terms expire, marking a shift toward a more conventional governance structure for the company’s remaining shareholders.
The most recent analyst rating on (SHC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
Spark’s Take on SHC Stock
According to Spark, TipRanks’ AI Analyst, SHC is a Neutral.
The score reflects improving operating performance and a supportive earnings update with reaffirmed guidance and reduced legal overhang, partially offset by a highly leveraged balance sheet and uneven free-cash-flow conversion. Technicals are mildly positive but not yet a strong long-term uptrend, while the high P/E and lack of dividend support weigh on valuation.
To see Spark’s full report on SHC stock, click here.
More about Sotera Health
Sotera Health Company operates in the healthcare services industry, focusing on sterilization, lab testing, and related safety solutions for medical and pharmaceutical customers. The company’s shareholder base has historically included private equity sponsors Warburg Pincus LLC and GTCR LLC, which held special corporate governance rights, including the ability to designate directors to its board.
Average Trading Volume: 3,263,357
Technical Sentiment Signal: Buy
Current Market Cap: $4.46B
See more insights into SHC stock on TipRanks’ Stock Analysis page.